benztropine and Vomiting

Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptothecin; Dexamethasone; Drug Combinations; Female; Fluorouracil; Haloperidol; Humans; Leucovorin; Male; Metoclopramide; Morpholines; Nausea; Organoplatinum Compounds; Pancreatic Neoplasms; Vomiting

Twenty-six children aged 4 to 15 years who were to receive cancer chemotherapy were enrolled in a double-blind, randomized, crossover trial that compared the antiemetic efficacy of a four-drug regimen (the MBDL regimen: metoclopramide, 8 mg/kg; benztropine, 0.04 mg/kg; dexamethasone, 0.7 mg/kg; lorazepam, 0.1 mg/kg), given over 24 hours, with the efficacy of chlorpromazine, 3.3 mg/kg, given in four doses over 24 hours. The MBDL regimen was more effective than chlorpromazine in both objective and subjective measures of antiemetic control. Of 26 children, 23 (89%) had less vomiting on the MBDL regimen, and 20 (77%) of 26 patients or parents preferred this regimen (p less than 0.01). The MBDL regimen reduced the number of vomiting episodes by a mean of 4.0 (p less than 0.01) and reduced the duration of vomiting by a mean of 3.7 hours (p less than 0.01). A moderate level of sedation was documented at some stage in the 24-hour period of observation in 27% on the MBDL regimen and in 35% receiving chlorpromazine. Dystonia was seen in 1 (4%) of 26 children. We conclude that the MBDL regimen is safe in children and more effective than chlorpromazine.

Topics: Adolescent; Antineoplastic Agents; Benztropine; Child; Child, Preschool; Chlorpromazine; Clinical Trials as Topic; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Metoclopramide; Random Allocation; Sleep Stages; Tropanes; Vomiting

Topics: Benztropine; Chemistry, Pharmaceutical; Dexamethasone; Diphenhydramine; Drug Combinations; Drug Compounding; Haloperidol; Humans; Lorazepam; Metoclopramide; Nausea; Suppositories; Vomiting

Topics: Adolescent; Antipsychotic Agents; Benztropine; Drug Interactions; Fluphenazine; Haloperidol; Humans; Male; Tropanes; Vomiting

The case of a 23-year-old patient treated with haloperidol, imipramine, and benztropine mesylate is presented to illustrate an unusually severe reaction to the abrupt cessation of neuroleptic medication. In addition to the description of the withdrawal reaction, a possible explanation of the clinical phenomenon is offered.

Topics: Adult; Benztropine; Depression; Drug Therapy, Combination; Haloperidol; Humans; Imipramine; Male; Schizophrenia; Substance Withdrawal Syndrome; Tropanes; Vomiting

Topics: Aged; Benztropine; Cecal Diseases; Constipation; Depression; Diarrhea; Enema; Female; Humans; Intestinal Obstruction; Intestinal Perforation; Male; Megacolon; Schizophrenia; Vomiting

Topics: Antiparkinson Agents; Benztropine; Child; Female; Humans; Infant; Injections, Intravenous; Male; Movement Disorders; Perphenazine; Poisoning; Vomiting